GlassScriptPhysician profile
Nora S Daher
NPI 1821265000
$8,938.71
in general payments reported to CMS, 2019-2025
34 companies · $1,830 in 2025
The $1,830 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $817 · 2021: $1,122 · 2022: $1,254 · 2023: $1,197 · 2024: $1,445 · 2025: $1,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,369 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,369.27 |
| Education | $101.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,507.90 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Genentech USA, INC. | $1,306.12 | 2019-2025 | Xolair |
| Genzyme Corporation | $1,287.41 | 2019-2025 | |
| Kaleo, INC. | $801.60 | 2019-2023 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $712.63 | 2019-2025 | |
| Glaxosmithkline, LLC. | $621.78 | 2019-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $592.84 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Pfizer INC. | $524.84 | 2019-2025 | |
| Amgen INC. | $351.73 | 2020-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $164.31 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $122.12 | 2019-2023 | Dupixent |
| Grifols USA, LLC | $115.66 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $83.43 | 2025 | Neffy |
| Blueprint Medicines Corporation | $80.48 | 2021-2025 | Ayvakit |
| Hikma Pharmaceuticals USA | $76.34 | 2023-2024 | Ryaltris |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $67.99 | 2024 | |
| Optinose US, INC. | $59.84 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.05 | 2020-2023 | Takhzyro |
| Sunovion Pharmaceuticals INC. | $42.18 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.92 | 2020-2022 | |
| Biocryst US Sales Co., LLC | $35.99 | 2021-2023 | Orladeyo |
| Alk-Abello, INC | $34.79 | 2020-2022 | |
| Incyte Corporation | $31.81 | 2022 | |
| Greer Laboratories, INC. | $30.74 | 2023 | Palforzia |
| Merck Sharp & Dohme LLC | $29.51 | 2021-2023 | |
| Leo Pharma INC. | $29.38 | 2022-2023 | Adbry |
| Ionis Pharmaceuticals, INC. | $20.27 | 2025 | |
| Circassia INC. | $18.70 | 2019 | |
| Lilly USA, LLC | $18.39 | 2025 | Ebglyss |
| Biocryst Pharmaceuticals, INC. | $17.13 | 2020 | |
| Octapharma USA, INC. | $16.02 | 2023 | Cutaquig |
| Galderma Laboratories, L.P. | $14.74 | 2025 | Nemluvio |
| Mylan Pharmaceuticals INC. | $11.34 | 2020 | |
| Cycle Pharmaceuticals INC | $9.73 | 2024 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Daher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.